Teriparatide Injection Generic Name & Formulations
Teriparatide (recombinant) 250mcg/mL; soln for SC inj; contains m-cresol.
Hormone (human parathyroid hormone, recombinant).
Single-patient-use pens (2.48mL)—1
Teriparatide Injection Indications
Postmenopausal osteoporosis in women who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. Treatment of men and women with osteoporosis associated with sustained glucocorticoid therapy at high risk for fracture (see full labeling).
Teriparatide Injection Dosage and Administration
20mcg SC once daily into thigh or abdominal wall; may treat for up to 2 years.
Teriparatide Injection Contraindications
Teriparatide Injection Boxed Warnings
Potential risk of osteosarcoma.
Teriparatide Injection Warnings/Precautions
Increased baseline risk for osteosarcoma (eg, Paget's disease of bone, unexplained increased alkaline phosphatase, open epiphyses, prior skeletal radiation therapy), bone metastases, history of skeletal malignancies, metabolic bone disease, hypercalcemia or risk thereof (eg, hyperparathyroidism): not recommended. Urolithiasis. Hypercalciuria. Hepatic, renal, or cardiac disease. Pregnancy. Nursing mothers: not recommended.
Teriparatide Injection Pharmacokinetics
Teriparatide Injection Interactions
Caution with digoxin (teriparatide-induced hypercalcemia increases risk of toxicity).
Teriparatide Injection Adverse Reactions
Arthralgia, pain, nausea; transient orthostatic hypotension, hypercalcemia, hyperuricemia, inj site reactions.
Teriparatide Injection Clinical Trials
Teriparatide Injection Note
Teriparatide Injection Patient Counseling